Moreover, to determine the translational impact of the TREM2/TREM1, and Olfr2 therapies, the development of induced pluripotent stem cells derived in-vitro vascular organoids may be beneficial to screen drugs that are more effective in lowering atherosclerosis disease burden in humans. The gene discussed is TREM1; the disease is atherosclerosis.